Insmed raises peak sales guidance to $14 billion
Insmed (INSM) raised peak sales guidance to $14 billion, citing strong BRINSUPRI and TPIP performance and expanding indications. It expects profitability next year.
Peak sales guidance was raised to $14 billion, driven by strong BRINSUPRI and TPIP performance and expanding indications. The BRINSUPRI launch exceeded benchmarks, with rapid patient uptake, high payer approval, and growing market potential. Profitability is expected next year.Based on Insmed Incor…